Skip to Content

Pfenex Inc.

Merger

  • Date:
  • 8/10/2020
  • Company Name:
  • Pfenex Inc.
  • Stock Symbol:
  • PFNX
  • Company Name - Buyer:
  • Ligand Pharmaceuticals, Inc.
  • Stock Symbol - Buyer:
  • LGND
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 8/10/2020

Case Finder

Locate any case using the tools below.

NEW YORK, August 10, 2020 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Pfenex Inc. (NYSE: PFNX) breached their fiduciary duties or violated the federal securities laws in connection with the company’s merger with Ligand Pharmaceuticals Inc. (NASDAQ: LGND).

On August 10, 2020, Pfenex announced that it had signed an agreement to be acquired by Ligand for approximately $438 million. Pursuant to the merger agreement, Pfenex’s stockholders will receive $12 in cash for each share of Pfenex common stock owned. In addition, Ligand will also pay Pfenex stockholders $2 per share as a Contingent Value Right (CVR) in the event a predefined regulatory milestone is achieved by December 31, 2021. The deal is scheduled to close in the fourth quarter of 2020.

Bragar Eagel & Squire is concerned that Pfenex’s board of directors oversaw an unfair process and ultimately agreed to an inadequate deal price. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Pfenex’s stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Pfenex Inc.. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: